Technical Analysis for AQST - Aquestive Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | -8.73% | |
| Wide Bands | Range Expansion | -8.73% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -11.86% | |
| Calm After Storm | Range Contraction | -11.86% | |
| NR7 | Range Contraction | -11.86% | |
| Lower Bollinger Band Walk | Weakness | -11.86% | |
| Wide Bands | Range Expansion | -11.86% | |
| Lower Bollinger Band Walk | Weakness | -12.36% | |
| Wide Bands | Range Expansion | -12.36% | |
| Lower Bollinger Band Touch | Weakness | -12.36% |
| Alert | Time |
|---|---|
| 2x Volume Pace | about 1 hour ago |
| 1.5x Volume Pace | about 1 hour ago |
| 3x Volume Pace | about 1 hour ago |
| Gapped Down (Full) | about 1 hour ago |
| Down 5% | about 1 hour ago |
Get a Trading Assistant
- Earnings date: 06/20/2024
Aquestive Therapeutics, Inc. Description
Aquestive Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on the development of treatments for diseases related to the central nervous system (CNS). Its CNS programs consist of a pipeline of products that include Libervant, Sympazan, and AQST-117. Libervant is a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. Sympazan is an oral soluble film formulation of clobazam for the treatment of seizures associated with a rare, intractable form of epilepsy known as Lennox-Gastaut Syndrome. AQST-117 is an oral soluble film formulation of riluzole for the treatment of Amyotrophic Lateral Sclerosis. The Company’s complex molecule programs consist of AQST-108, and AQST-305, for the treatment of anaphylaxis and neuroendocrine tumors respectively. The Company also has a pipeline of products under partner programs, which includes Suboxone and APL-130277 for the treatment of opioid dependence, and Parkinson’s disease.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Pharmaceutical Disease Drugs Psychoactive Drugs Opioids Epilepsy Amyotrophic Lateral Sclerosis Chloroarenes Seizure Gabaa Receptor Positive Allosteric Modulators Neuroendocrine Tumors Neuroendocrine Tumor Parkinson’s Disease Anaphylaxis Riluzole
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.23 |
| 52 Week Low | 1.2514 |
| Average Volume | 3,220,970 |
| 200-Day Moving Average | 2.53 |
| 50-Day Moving Average | 4.25 |
| 20-Day Moving Average | 3.85 |
| 10-Day Moving Average | 3.60 |
| Average True Range | 0.36 |
| RSI (14) | 39.76 |
| ADX | 18.52 |
| +DI | 18.94 |
| -DI | 26.45 |
| Chandelier Exit (Long, 3 ATRs) | 3.47 |
| Chandelier Exit (Short, 3 ATRs) | 4.13 |
| Upper Bollinger Bands | 4.55 |
| Lower Bollinger Band | 3.16 |
| Percent B (%b) | 0.16 |
| BandWidth | 35.94 |
| MACD Line | -0.20 |
| MACD Signal Line | -0.14 |
| MACD Histogram | -0.0627 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 3.69 | ||||
| Resistance 3 (R3) | 3.69 | 3.60 | 3.64 | ||
| Resistance 2 (R2) | 3.60 | 3.52 | 3.59 | 3.62 | |
| Resistance 1 (R1) | 3.49 | 3.47 | 3.44 | 3.48 | 3.60 |
| Pivot Point | 3.39 | 3.39 | 3.37 | 3.39 | 3.39 |
| Support 1 (S1) | 3.28 | 3.31 | 3.24 | 3.28 | 3.16 |
| Support 2 (S2) | 3.19 | 3.26 | 3.18 | 3.14 | |
| Support 3 (S3) | 3.08 | 3.19 | 3.12 | ||
| Support 4 (S4) | 3.07 |
